Marker Therapeut Stock Price, News & Analysis

Marker Therapeutics (NASDAQ:MRKR) announced that the FDA has granted Orphan Drug designation to MT-601, a T cell product targeting pancreatic cancer. The designation highlights MT-601’s potential to treat a disease with a low 5-year survival rate. The product targets multiple tumor-associated antigens and is in a Phase 1 trial showing promising results. The company plans to initiate a multicenter study combining MT-601 with chemotherapy and file an Investigational New Drug Application in 2022. Orphan designation may provide various benefits, including market exclusivity.

Marker Therapeutics (NASDAQ: MRKR) has appointed Dr. Katharine Knobil to its Board of Directors, bringing over 20 years of leadership in clinical development, notably at GlaxoSmithKline. This strategic move is expected to enhance Marker’s capabilities as it develops novel T cell therapies for cancer treatment. Dr. Knobil currently serves as Chief Medical Officer at Agilent Technologies and holds prior roles at Kaleido Biosciences. Her expertise may contribute significantly as Marker Therapeutics advances its immunotherapy initiatives.

Marker Therapeutics (NASDAQ: MRKR) announced that data from its Phase 1 study on MultiTAA-specific T cells will be presented at the 2021 ASH Annual Meeting, set for December 11-14 in Atlanta and virtually. The oral presentation, titled "Donor-Derived Adoptive T-Cell Therapy Targeting Multiple Tumor Associated Antigens to Prevent Post-Transplant Relapse in Patients with ALL," will occur on December 12 at 12:30 p.m. ET. The study, conducted in partnership with Baylor College of Medicine, showcases Marker's innovative approach to T cell-based immunotherapies for hematological malignancies.

Marker Therapeutics, Inc. (Nasdaq:MRKR) provided a corporate update and reported Q3 2021 financial results. They continue to advance the Phase 2 trial of MT-401 for post-transplant AML, with first patients dosed and plans to enroll 20 patients by Q4 2021. The company’s cGMP manufacturing facility is operational, supporting ongoing operations and potential future trials. Financially, Marker had cash reserves of $48.7 million, enough to fund operations into Q1 2023. However, the net loss for Q3 2021 was $12.4 million, up from $7.4 million in Q3 2020.

Marker Therapeutics, Inc. (NASDAQ: MRKR), a leader in clinical-stage immuno-oncology, will present at three virtual investor conferences this September. The conferences include the H.C. Wainwright Annual Global Investment Conference on September 13, the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, and the Cantor Fitzgerald Global Healthcare Conference on September 27. Presentations will feature key executives, including CFO Anthony H. Kim and CMO Mythili Koneru. Webcasts will be available on the company’s website.

Marker Therapeutics, Inc. (Nasdaq: MRKR) has received a $13.1 million Product Development Research award from the Cancer Prevention and Research Institute of Texas (CPRIT) to support its Phase 2 clinical trial of MT-401, specifically for patients with acute myeloid leukemia (AML) post-hematopoietic stem cell transplant. The trial's focus is on evaluating relapse-free survival in patients treated with MT-401 versus a control group. This funding underscores CPRIT's commitment to advancing cancer research, having awarded over $2.9 billion to Texas institutions since its inception.

Marker Therapeutics (MRKR) provided a corporate update and financial results for Q2 2021, reporting a net loss of $10.9 million, up from $6.3 million in Q2 2020. The company completed the safety lead-in for its Phase 2 trial on MultiTAA-specific T cell therapy for AML and is enrolling patients for the main trial. Marker opened a new cGMP manufacturing facility in Houston, expected to lower costs and improve patient access. With $57.2 million in cash, the company anticipates funding through Q1 2023.

Marker Therapeutics (Nasdaq: MRKR) announces the opening of its new cGMP manufacturing facility in Houston, TX. This facility will support the Phase 2 acute myeloid leukemia (AML) trial, aiming to enroll 160 patients. The modular facility, spanning 48,500 square feet and currently utilizing a third of its space, represents a strategic goal to enhance therapy access and reduce manufacturing costs. This development is crucial for the company's MultiTAA-specific T cell products, aiming to facilitate future clinical trials and potential commercialization of approved products.

Marker Therapeutics, Inc. (Nasdaq:MRKR) announced the completion of the six-patient safety lead-in phase of its Phase 2 trial for MT-401, targeting post-transplant acute myeloid leukemia (AML). All participants met safety endpoints following treatment with the MultiTAA-specific T cell therapy. The ongoing trial aims to evaluate MT-401's efficacy against AML in both adjuvant and active disease settings, with a total of approximately 160 patients involved. The FDA previously granted Orphan Drug designation to MT-401, highlighting its potential in addressing unmet needs in AML treatment.